TRECs levels in PID patients after HSCT
We followed up TRECs levels in five patients with classical WAS and two
with CGD who underwent HSCT (Fig. 9). The clinical features of these
patients are summarized in Table 5. Patients P2 and P5 characterized by
respiratory tract infections, eczema, and thrombocytopenia. P2 developed
GVHD in the liver, eyes, and CNS after HSCT, and P5 suffered multiple
organs disorders. P6 on set with systemic tuberculosis after BCG
vaccination and suffered liver and kidney damage after HSCT. P2, P5, and
P6 had low levels of TRECs up until 4 weeks after HSCT. The other four
patients showed elevated TRECs levels in the following 4 weeks, which
returned to the normal range at around 1 year post-HSCT.